TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
Enhancer of zeste homolog 2 (EZH2) expression is found in about 40% of mantle cell lymphoma (MCL) patients, which is associated with aggressive histology, high Ki-67 proliferation rate, p53 mutant pattern and inferior overall survival (OS). We conducted 11-gene (ATM, BIRC3, CCND1, KMT2C, KMT2D, NOTCH1, NOTCH2, RB1, TP53, TRAF2 and UBR5) next generation sequencing panel to shed more light on MCL with EZH2 expression (EZH2+ MCL). EZH2+ MCL more frequently harbor TP53 mutation compared to EZH2(-) MCL (41.2% vs. 19.1%, respectively, p = 0.045). TP53 mutation and EZH2 expression demonstrated overlapping features including aggressive histology, high Ki-67 proliferation rate and p53 mutant pattern by immunohistochemistry. Comparative analysis disclosed that EZH2 expression correlates with high Ki-67 proliferation rate irrespective of TP53 mutation. Aggressive histology is associated with EZH2 expression or TP53 mutation, possibly via independent mechanisms. p53 mutant pattern is due to TP53 mutation. MCL patients with EZH2 expression or TP53 mutation show inferior outcome and when both are present, patients have dismal outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:146 |
|---|---|
| Enthalten in: |
Human pathology - 146(2024) vom: 07. März, Seite 1-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Do Hwan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 13.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.humpath.2024.03.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36950531X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36950531X | ||
| 003 | DE-627 | ||
| 005 | 20240314235419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240310s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.humpath.2024.03.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM36950531X | ||
| 035 | |a (NLM)38460798 | ||
| 035 | |a (PII)S0046-8177(24)00038-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Do Hwan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Enhancer of zeste homolog 2 (EZH2) expression is found in about 40% of mantle cell lymphoma (MCL) patients, which is associated with aggressive histology, high Ki-67 proliferation rate, p53 mutant pattern and inferior overall survival (OS). We conducted 11-gene (ATM, BIRC3, CCND1, KMT2C, KMT2D, NOTCH1, NOTCH2, RB1, TP53, TRAF2 and UBR5) next generation sequencing panel to shed more light on MCL with EZH2 expression (EZH2+ MCL). EZH2+ MCL more frequently harbor TP53 mutation compared to EZH2(-) MCL (41.2% vs. 19.1%, respectively, p = 0.045). TP53 mutation and EZH2 expression demonstrated overlapping features including aggressive histology, high Ki-67 proliferation rate and p53 mutant pattern by immunohistochemistry. Comparative analysis disclosed that EZH2 expression correlates with high Ki-67 proliferation rate irrespective of TP53 mutation. Aggressive histology is associated with EZH2 expression or TP53 mutation, possibly via independent mechanisms. p53 mutant pattern is due to TP53 mutation. MCL patients with EZH2 expression or TP53 mutation show inferior outcome and when both are present, patients have dismal outcome | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Siddiqui, Saima |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Preetesh |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Thakral, Beenu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shaoying |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Vega, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Medeiros, L Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Ok, Chi Young |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human pathology |d 1998 |g 146(2024) vom: 07. März, Seite 1-7 |w (DE-627)NLM000167614 |x 1532-8392 |7 nnns |
| 773 | 1 | 8 | |g volume:146 |g year:2024 |g day:07 |g month:03 |g pages:1-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.humpath.2024.03.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 146 |j 2024 |b 07 |c 03 |h 1-7 | ||